Matches in Nanopublications for { ?s ?p "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP577101.RARHdrsz7G-o7ujZEji1uI5gswv8sWdziuxI2slMSE0yM130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP577101.RARHdrsz7G-o7ujZEji1uI5gswv8sWdziuxI2slMSE0yM130_provenance.
- NP219544.RAQTRcDdNUoXINJUVlnyRnqk6UX8HXUSIWS6Ha7T6JHAc130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219544.RAQTRcDdNUoXINJUVlnyRnqk6UX8HXUSIWS6Ha7T6JHAc130_provenance.
- NP1151553.RAAa9cMei4isyJRNfCJ02sd6QV-9iXIzaTUeTkcGCMkio130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151553.RAAa9cMei4isyJRNfCJ02sd6QV-9iXIzaTUeTkcGCMkio130_provenance.
- NP1151556.RAUuuiPEPTKZNso8tRPGcmkWorYr_-unPm6lJzu9Qn6Ag130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151556.RAUuuiPEPTKZNso8tRPGcmkWorYr_-unPm6lJzu9Qn6Ag130_provenance.
- NP1151552.RAoLrFJrvBgyOqgTBPNw-x02RIjnHN2bToA2kPlXYMnFM130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151552.RAoLrFJrvBgyOqgTBPNw-x02RIjnHN2bToA2kPlXYMnFM130_provenance.
- NP219117.RAzsVy7OUPcM6esoSx64ActWs9XCJntxct0xnzIyVccho130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219117.RAzsVy7OUPcM6esoSx64ActWs9XCJntxct0xnzIyVccho130_provenance.
- NP576928.RA-DPr98JCjosJ_eRlERMdKomJ7XZ7-as-ANYSpdtuhkA130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576928.RA-DPr98JCjosJ_eRlERMdKomJ7XZ7-as-ANYSpdtuhkA130_provenance.
- NP712097.RA_-9CiUXIbTCVsgqcgV5Ef_UWGqRVAiWI5Mt7CZVYcmw130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP712097.RA_-9CiUXIbTCVsgqcgV5Ef_UWGqRVAiWI5Mt7CZVYcmw130_provenance.
- NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_provenance.
- NP1151554.RAyd9t1GY2v_3gRos0EPc9w469-0YdOYSjCIoQbPsfF_A130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151554.RAyd9t1GY2v_3gRos0EPc9w469-0YdOYSjCIoQbPsfF_A130_provenance.